Retatrutide (developmental code LY3437943) is a once-weekly injectable peptide that simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. It is the most clinically advanced triple agonist compound in published literature and is currently progressing through Eli Lilly's Phase 3 TRIUMPH trial programme. BodyPharm UAE supplies retatrutide 32mg for laboratory and research use across the UAE and GCC.
what is retatrutide?.
Retatrutide is a synthetic peptide agonist developed by Eli Lilly and Company, designated LY3437943 in clinical literature. It is classified as a first-in-class GIP/GLP-1/glucagon triple receptor agonist - meaning it engages all three receptors through a single molecule rather than through a combined formulation.
This distinguishes it from earlier compounds in the incretin class. Semaglutide acts exclusively at the GLP-1 receptor. Tirzepatide, the first approved dual agonist, combines GLP-1 and GIP activity. Retatrutide adds a third pathway - glucagon receptor agonism - which introduces distinct metabolic effects not observed with dual agonism alone.
mechanism of action: three receptor pathways.
Understanding retatrutide's research profile requires understanding each of the three receptor pathways it engages.
is the most extensively characterised pathway in this compound class. Published literature documents its role in glucose-dependent insulin secretion, modulation of gastric emptying, and central appetite signalling. GLP-1 agonism forms the mechanistic backbone of the entire incretin-based research field.
adds a second incretin pathway. Preclinical research suggests GIP agonism may enhance insulin sensitivity in adipose tissue and contribute to lipid metabolism effects not consistently observed with GLP-1 alone. Tirzepatide established the dual GLP-1/GIP model commercially; retatrutide builds on this architecture.
is what makes retatrutide mechanistically unique within its class. In isolation, glucagon receptor activation increases hepatic glucose output, which would raise blood glucose. When combined with GLP-1 and GIP agonism, the insulinotropic effects counterbalance the glycemic impact while preserving the metabolic rate increase from glucagon activity. Researchers studying the glucagon pathway have noted its role in hepatic fat metabolism and thermogenic energy expenditure - areas of active investigation in the TRIUMPH trial programme.
phase 2 clinical trial data.
Retatrutide has been evaluated in two published Phase 2 randomised controlled trials - one in participants with obesity and one in participants with type 2 diabetes and overweight or obesity. Both trials were published in peer-reviewed journals in 2023. A substudy examining hepatic fat outcomes was published in Nature Medicine in 2024. These trials provide the primary published dataset for retatrutide's receptor engagement profile across metabolic research domains. The full trial data is available via the published peer-reviewed literature for research reference.
phase 3 programme: triumph trials.
Retatrutide is currently being studied in several Phase 3 clinical trials under Eli Lilly's TRIUMPH programme, evaluating its potential efficacy and safety across obesity and overweight, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.
The Phase 3 TRIUMPH-4 trial, a 68-week randomised double-blind placebo-controlled study, reported positive topline results in December 2025, evaluating retatrutide in adults with obesity or overweight and knee osteoarthritis. This was the first Phase 3 trial in the TRIUMPH programme to report results.
Regulatory approval timelines remain subject to the completion of the full Phase 3 dataset and FDA review processes.
how retatrutide compares to other incretin compounds.
Researchers working across the GLP-1 and dual-agonist literature will note the following structural differences when evaluating retatrutide:
Retatrutide adds GIP and glucagon receptor activity to the GLP-1 backbone, engaging two additional receptor pathways not covered by mono-agonism. Direct head-to-head trial data comparing the two compounds has not yet been published.
The addition of glucagon receptor agonism is the key mechanistic distinction. The specific contribution of the glucagon pathway to the overall research profile of retatrutide remains an active area of investigation.
Retatrutide is currently the only triple GLP-1/GIP/glucagon agonist with published Phase 2 data in both obesity and type 2 diabetes populations.
active research areas.
Based on published literature and the ongoing TRIUMPH programme, the following areas represent the current focus of retatrutide research:
Early data from the hepatic fat substudy has prompted broader investigation into retatrutide's potential in liver disease research contexts.
Isolating the specific contribution of glucagon receptor agonism within the triple agonist model remains an open research question.
How metabolic changes are maintained beyond the active treatment period is a key question the Phase 3 programme is designed to address.
Researchers are evaluating how tri-agonism compares mechanistically to combination protocols such as GLP-1 agonist plus amylin analogue approaches.
storage and handling for laboratory use.
Retatrutide supplied by BodyPharm UAE is provided as a lyophilised powder. Standard laboratory handling protocols apply:
- Store unreconstituted vials at 2°C to 8°C, away from direct light
- Reconstitute using bacteriostatic water; add liquid slowly against the vial wall and swirl gently rather than shaking
- Use reconstituted solution within standard stability windows for peptide compounds
- Each vial is supplied with a batch-specific Certificate of Analysis (CoA) confirming purity
supply in the uae and gcc.
BodyPharm UAE supplies Retatrutide 32mg for laboratory and research purposes across the UAE and GCC. All orders include a Certificate of Analysis and are packaged for temperature integrity in transit. Delivery covers Dubai, Abu Dhabi, Sharjah, and the wider GCC including Saudi Arabia, Qatar, Kuwait, Oman, and Bahrain.
All compounds supplied by BodyPharm UAE are strictly for in vitro and laboratory research use only. Not for human or animal consumption.
frequently asked questions.
Retatrutide (LY3437943) is an investigational once-weekly peptide that activates GLP-1, GIP, and glucagon receptors simultaneously. It is developed by Eli Lilly and is currently in Phase 3 clinical trials.
Semaglutide is a GLP-1 mono-agonist. Retatrutide activates two additional receptor pathways - GIP and glucagon - in a single molecule, producing a broader metabolic receptor engagement profile.
Tirzepatide is a GLP-1/GIP dual agonist. Retatrutide adds glucagon receptor agonism as a third pathway, which is hypothesised to contribute to hepatic fat reduction and thermogenic energy expenditure effects beyond dual agonism.
No. Retatrutide is investigational and currently in Phase 3 trials. It is not approved for clinical or therapeutic use in any jurisdiction.
BodyPharm UAE supplies research-grade retatrutide 32mg to laboratories and research institutions across the UAE and GCC. Supply enquiries can be directed to bodypharm.ae.
All BodyPharm UAE peptides are supplied with a batch-specific Certificate of Analysis verifying purity via HPLC and mass spectrometry.
BodyPharm UAE supplies Retatrutide 32mg for research use with same-day delivery across Dubai. View the complete research peptide catalogue for all available compounds.
BodyPharm products are sold strictly for research purposes only and are not intended for human consumption, diagnosis, or treatment.
Related Research
Semaglutide in Dubai: what researchers need to know in 2025
Research guide to Semaglutide in Dubai and the UAE. What published science says about this GLP-1 receptor agonist peptid...
Peptide research Dubai: a guide to the most popular research peptides in 2025
Explore the most researched peptides available in Dubai and the UAE. A research-focused overview of popular research pep...
GHK-Cu peptide in the UAE: research applications and sourcing guide
Research guide to GHK-Cu in the UAE. The science on this copper peptide, its tissue and skin biology mechanisms, and sou...